market news Archives | BioInformant

Market Forces Affecting the Cord Blood and Cord Tissue Industry

September 9, 2025 By Cade Hildreth, Founder & President Leave a Comment

Recently released, the “Global Cord Blood & Tissue Banking Industry Report – Market Size, Segmentation, and Forecasts” explores clinical trial market data supporting applications for hematopoietic stem cells (HSCs) from cord blood and mesenchymal stem cells (MSCs) from cord tissue. Within this rapidly evolving marketplace, those who choose to commit to understanding current opportunities and threats will be positioned for a substantial strategic advantage.

Because the global cord blood banking industry has matured substantially over the past few years, new market forces have created both serious threats and novel opportunities. [Read more…]

Interview with Accellta’s Intellectual Property (IP) Officer, Eran Cohen

August 3, 2024 By Cade Hildreth, Founder & President Leave a Comment

This is an follow-up to our interview with Accellta’s CEO, Dr. Itzchak Angel, who highlighted Accellta’s unique technologies for enabling large scale growth of cells in suspension. This interview features insights from Eran Cohen, Accellta’s head of business development and intellectual property (IP) officer.

[Read more…]

Cynata’s “Major Breakthrough” in MSC Manufacturing – Unlimited Quantities, Uniform Batches, Single Donor, & Low Cost

November 22, 2018 By Cade Hildreth, Founder & President Leave a Comment

For years, it has been clear that mesenchymal stem cells (MSCs) are a leading type of stem cell being investigated for therapeutic applications, as they have the potential to treat a wide range of acute and degenerative diseases. In addition to secreting factors that can stimulate tissue repair, MSCs can substantially alter their microenvironment, exerting effects that are both anti-inflammatory and anti-fibrotic.

MSCs are also advantageous over other stem cells types, because they avoid the ethical issues that surround embryonic stem cell research and appear to be immuno-privileged. Importantly, MSCs also well-suited for use in the exponential growth area of 3D printing, because of their unusual capacity to form structural tissues. [Read more…]

ORIG3N, World’s Largest Blood Cell Repository for iPS Cell Production

December 12, 2017 By Cade Hildreth, Founder & President Leave a Comment

ORIG3N, an innovative biotech company that creating the world’s largest blood cell repository for induced pluripotent stem cell (iPS cell) production. I first met James Lovgren, Chief Business Officer of ORIG3N, at the World Stem Cell Summit in 2015. As a result of that connection and conversation, I am pleased to share this interview with him below. [Read more…]

Major Week for Stem Cells – Acquisitions, Investments, License Agreements, and More

May 12, 2016 By Cade Hildreth, Founder & President Leave a Comment

We’ve released new content on stem cell markets that we are excited to share with you. Let me know what you think?

CellPlan Launches The World’s First Global Stem Cell Healthcare Plan

CellPlan today announced the creation of the world’s first global stem cell healthcare plan, which will be launched at the World Cord Blood Congress Europe 2016 in London this month. The UK company said that the new medical insurance product could revolutionize stem cell healthcare by making stem cell transplants affordable for families who require treatment for life threatening diseases. [Read more…]